[18F]-flutemetamol amyloid imaging along the continuum from normal cognitive status to Alzheimer's disease dementia.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1091220124

Enrollment

120

Registered

2013-04-09

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimers disease, mild cognitive impairment (MCI), and cognitive intact healthy control (HC) subjects

Interventions

Intervention type:DRUG Name of intervention:[18F]-flutemetamol Dose form / Japanese Medical Device Nomenclature:INJECTION Route of administration / Site of application:INTRAVENOUS BOLUS Dose per admi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AD, MCI and HC subjects undergo cognitive testing, [11C]-PIB PET and [18F]-flutemetamol PET. Informed consent is obtained.

Exclusion criteria

Exclusion criteria: Other degenerative disease

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the efficacy of blinded visual assessments of 18F-flutemetamol scans in AD, MCI and HC subjects with and without PIB retention.	—

Secondary

Measure	Time frame
The clinical disease stages of AD are divided into three phases; pre-symptomatic AD, prodromal AD and AD dementia, with [18F]-flutemetamol PET image and cognitive function.	—

Countries

Japan

Contacts

Public ContactShizuo Hatashita

Shonan-Atsugi Hospital

hatashita@shonan-atsugi.jp+81-46-223-3636

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026